References
- Stadler, Z.K., et al., Genome-wide association studies of cancer. J Clin Oncol, 2010. 28(27): p. 4255-67.
- Foulkes, W.D., Inherited susceptibility to common cancers. N Engl J Med, 2008. 359(20): p. 2143-53.
- Ford, D., et al., Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet, 1998. 62(3): p. 676-89.
- Yurgelun, M.B., E. Hiller, and J.E. Garber, Population-Wide Screening for Germline BRCA1 and BRCA2 Mutations: Too Much of a Good Thing? J Clin Oncol, 2015.
- Tsigginou, A., et al., Cumulative BRCA mutation analysis in the Greek population confirms that homogenous ethnic background facilitates genetic testing. Hered Cancer Clin Pract, 2015. 13(1): p. 17.
- Fostira, F., et al., Prevalence of BRCA1 mutations among 403 women with triple-negative breast cancer: implications for genetic screening selection criteria: a Hellenic Cooperative Oncology Group Study. Breast Cancer Res Treat, 2012. 134(1): p. 353-62.
- Stavropoulou, A.V., et al., Prevalence of BRCA1 mutations in familial and sporadic greek ovarian cancer cases. PLoS One, 2013. 8(3): p. e58182.
- Petrucelli, N., M.B. Daly, and G.L. Feldman, BRCA1 and BRCA2 Hereditary Breast and Ovarian Cancer, in GeneReviews(R), R.A. Pagon, et al., Editors. 1993: Seattle (WA).
- Litton, J.K., et al., Earlier age of onset of BRCA mutation-related cancers in subsequent generations. Cancer, 2012. 118(2): p. 321-5.
- Martinez-Delgado, B., et al., Genetic anticipation is associated with telomere shortening in hereditary breast cancer. PLoS Genet, 2011. 7(7): p. e1002182.
- Lubinski, J., et al., Cancer variation associated with the position of the mutation in the BRCA2 gene. Fam Cancer, 2004. 3(1): p. 1-10.
- Masciari, S., et al., Breast cancer phenotype in women with TP53 germline mutations: a Li-Fraumeni syndrome consortium effort. Breast Cancer Res Treat, 2012. 133(3): p. 1125-30.
- Riley, B.D., et al., Essential elements of genetic cancer risk assessment, counseling, and testing: updated recommendations of the National Society of Genetic Counselors. J Genet Couns, 2012. 21(2): p. 151-61.
- Robson, M.E., et al., American Society of Clinical Oncology Policy Statement Update: Genetic and Genomic Testing for Cancer Susceptibility. J Clin Oncol, 2015.
- Kurian, A.W., et al., Performance of prediction models for BRCA mutation carriage in three racial/ ethnic groups: findings from the Northern California Breast Cancer Family Registry. Cancer Epidemiol Biomarkers Prev, 2009. 18(4): p. 1084-91.
- NCCN, www.nccn.org(last accessed on 20 Jul 2015).
- Daly, M.B., et al., Genetic/familial high-risk assessment: breast and ovarian. J Natl Compr Canc Netw, 2010. 8(5): p. 562-94.
- Saslow, D., et al., American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J Clin, 2007. 57(2): p. 75-89.
- Scheuer, L., et al., Outcome of preventive surgery and screening for breast and ovarian cancer in BRCA mutation carriers. J Clin Oncol, 2002. 20(5): p. 1260-8.
- Bick, U., Intensified surveillance for early detection of breast cancer in high-risk patients. Breast Care (Basel), 2015. 10(1): p. 13-20.
- Chiarelli, A.M., et al., Effectiveness of screening with annual magnetic resonance imaging and mammography: results of the initial screen from the ontario high risk breast screening program. J Clin Oncol, 2014. 32(21): p. 2224-30.
- Narod, S.A., et al., Screening mammography and risk of breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Lancet Oncol, 2006. 7(5): p. 402-6.
- Kauff, N.D., et al., Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med, 2002. 346(21): p. 1609-15.
- Rebbeck, T.R., et al., Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med, 2002. 346(21): p. 1616-22.
- Finch, A.P., et al., Impact of oophorectomy on cancer incidence and mortality in women with a BRCA1 or BRCA2 mutation. J Clin Oncol, 2014. 32(15): p. 1547-53.
- Narod, S.A., et al., Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Hereditary Breast Cancer Clinical Study Group. Lancet, 2000. 356(9245): p. 1876-81.
- King, M.C., et al., Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial. JAMA, 2001. 286(18): p. 2251-6.
- Cibula, D., et al., Oral contraceptives and risk of ovarian and breast cancers in BRCA mutation carriers: a meta-analysis. Expert Rev Anticancer Ther, 2011. 11(8): p. 1197-207.
- Iodice, S., et al., Oral contraceptive use and breast or ovarian cancer risk in BRCA1/2 carriers: a metaanalysis. Eur J Cancer, 2010. 46(12): p. 2275-84.
- Tutt A, et al: The TNT trial. 2014 San Antonio Breast Cancer Symposium. Abstract S3-01. Presented December 11, 2014.
- Walsh, C.S., Two decades beyond BRCA1/2: Homologous recombination, hereditary cancer risk and a target for ovarian cancer therapy. Gynecol Oncol, 2015. 137(2): p. 343-50.
- Kurian, A.W. and J.M. Ford, Multigene Panel Testing in Oncology Practice: How Should We Respond? JAMA Oncol, 2015. 1(3): p. 277-8.
- Desmond, A., et al., Clinical Actionability of Multigene Panel Testing for Hereditary Breast and Ovarian Cancer Risk Assessment. JAMA Oncol, 2015. 1(7): p. 943-51.
- Gaudet, M.M., et al., Identification of a BRCA2-specific modifier locus at 6p24 related to breast cancer risk. PLoS Genet, 2013. 9(3): p. e1003173.
- Couch, F.J., et al., Genome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer risk. PLoS Genet, 2013. 9(3): p. e1003212.
- King, M.C., E. Levy-Lahad, and A. Lahad, Population-based screening for BRCA1 and BRCA2: 2014 Lasker Award. JAMA, 2014. 312(11): p. 1091-2.
- Georgios Lypas, K.P., Georgia Georgiou, Menelaos Zoulamoglou, Nikolaos Tsoukalas, Georgios Zografos, Pavlos Papakostas, Vasileios Barbounis, Identification of breast cancer patients fulfilling NCCN criteria for genetic risk assessment. J Clin Oncol 31, 2013 (suppl; abstr e12537).
- Armstrong, J., et al., Utilization and Outcomes of BRCA Genetic Testing and Counseling in a National Commercially Insured Population: The ABOUT Study. JAMA Oncol, 2015. 1(9): p. 1251-60.
- Robson, M.E., et al., American Society of Clinical Oncology policy statement update: genetic and genomic testing for cancer susceptibility. J Clin Oncol, 2010. 28(5): p. 893-901.